The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Amyotrophic Lateral Sclerosis Therapeutics Market Research Report 2025
Synopsis
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The global Amyotrophic Lateral Sclerosis Therapeutics market was valued at US$ 300 million in 2023 and is anticipated to reach US$ 396.8 million by 2030, witnessing a CAGR of 3.4% during the forecast period 2024-2030.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
This report aims to provide a comprehensive presentation of the global market for Amyotrophic Lateral Sclerosis Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amyotrophic Lateral Sclerosis Therapeutics.
Report Scope
The Amyotrophic Lateral Sclerosis Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Amyotrophic Lateral Sclerosis Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Amyotrophic Lateral Sclerosis Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Segment by Type
Riluzole
Edaravone (Radicava)
Other
Segment by Application
Hospital
Drugs Store
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Amyotrophic Lateral Sclerosis Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The global Amyotrophic Lateral Sclerosis Therapeutics market was valued at US$ 300 million in 2023 and is anticipated to reach US$ 396.8 million by 2030, witnessing a CAGR of 3.4% during the forecast period 2024-2030.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
This report aims to provide a comprehensive presentation of the global market for Amyotrophic Lateral Sclerosis Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amyotrophic Lateral Sclerosis Therapeutics.
Report Scope
The Amyotrophic Lateral Sclerosis Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Amyotrophic Lateral Sclerosis Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Amyotrophic Lateral Sclerosis Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Segment by Type
Riluzole
Edaravone (Radicava)
Other
Segment by Application
Hospital
Drugs Store
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Amyotrophic Lateral Sclerosis Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Amyotrophic Lateral Sclerosis Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Riluzole
1.2.3 Edaravone (Radicava)
1.2.4 Other
1.3 Market by Application
1.3.1 Global Amyotrophic Lateral Sclerosis Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Drugs Store
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Amyotrophic Lateral Sclerosis Therapeutics Market Perspective (2019-2030)
2.2 Amyotrophic Lateral Sclerosis Therapeutics Growth Trends by Region
2.2.1 Global Amyotrophic Lateral Sclerosis Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Amyotrophic Lateral Sclerosis Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Amyotrophic Lateral Sclerosis Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Amyotrophic Lateral Sclerosis Therapeutics Market Dynamics
2.3.1 Amyotrophic Lateral Sclerosis Therapeutics Industry Trends
2.3.2 Amyotrophic Lateral Sclerosis Therapeutics Market Drivers
2.3.3 Amyotrophic Lateral Sclerosis Therapeutics Market Challenges
2.3.4 Amyotrophic Lateral Sclerosis Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Amyotrophic Lateral Sclerosis Therapeutics Players by Revenue
3.1.1 Global Top Amyotrophic Lateral Sclerosis Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Amyotrophic Lateral Sclerosis Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Amyotrophic Lateral Sclerosis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Amyotrophic Lateral Sclerosis Therapeutics Revenue
3.4 Global Amyotrophic Lateral Sclerosis Therapeutics Market Concentration Ratio
3.4.1 Global Amyotrophic Lateral Sclerosis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Amyotrophic Lateral Sclerosis Therapeutics Revenue in 2023
3.5 Amyotrophic Lateral Sclerosis Therapeutics Key Players Head office and Area Served
3.6 Key Players Amyotrophic Lateral Sclerosis Therapeutics Product Solution and Service
3.7 Date of Enter into Amyotrophic Lateral Sclerosis Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Amyotrophic Lateral Sclerosis Therapeutics Breakdown Data by Type
4.1 Global Amyotrophic Lateral Sclerosis Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Amyotrophic Lateral Sclerosis Therapeutics Forecasted Market Size by Type (2025-2030)
5 Amyotrophic Lateral Sclerosis Therapeutics Breakdown Data by Application
5.1 Global Amyotrophic Lateral Sclerosis Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Amyotrophic Lateral Sclerosis Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Amyotrophic Lateral Sclerosis Therapeutics Market Size (2019-2030)
6.2 North America Amyotrophic Lateral Sclerosis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Amyotrophic Lateral Sclerosis Therapeutics Market Size by Country (2019-2024)
6.4 North America Amyotrophic Lateral Sclerosis Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Amyotrophic Lateral Sclerosis Therapeutics Market Size (2019-2030)
7.2 Europe Amyotrophic Lateral Sclerosis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Amyotrophic Lateral Sclerosis Therapeutics Market Size by Country (2019-2024)
7.4 Europe Amyotrophic Lateral Sclerosis Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Amyotrophic Lateral Sclerosis Therapeutics Market Size (2019-2030)
9.2 Latin America Amyotrophic Lateral Sclerosis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Amyotrophic Lateral Sclerosis Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Amyotrophic Lateral Sclerosis Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Amyotrophic Lateral Sclerosis Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Amyotrophic Lateral Sclerosis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Amyotrophic Lateral Sclerosis Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Amyotrophic Lateral Sclerosis Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Mitsubishi Tanabe Pharma
11.1.1 Mitsubishi Tanabe Pharma Company Detail
11.1.2 Mitsubishi Tanabe Pharma Business Overview
11.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Therapeutics Introduction
11.1.4 Mitsubishi Tanabe Pharma Revenue in Amyotrophic Lateral Sclerosis Therapeutics Business (2019-2024)
11.1.5 Mitsubishi Tanabe Pharma Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Detail
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Amyotrophic Lateral Sclerosis Therapeutics Introduction
11.2.4 Sanofi Revenue in Amyotrophic Lateral Sclerosis Therapeutics Business (2019-2024)
11.2.5 Sanofi Recent Development
11.3 Mylan Pharma
11.3.1 Mylan Pharma Company Detail
11.3.2 Mylan Pharma Business Overview
11.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis Therapeutics Introduction
11.3.4 Mylan Pharma Revenue in Amyotrophic Lateral Sclerosis Therapeutics Business (2019-2024)
11.3.5 Mylan Pharma Recent Development
11.4 Apotex
11.4.1 Apotex Company Detail
11.4.2 Apotex Business Overview
11.4.3 Apotex Amyotrophic Lateral Sclerosis Therapeutics Introduction
11.4.4 Apotex Revenue in Amyotrophic Lateral Sclerosis Therapeutics Business (2019-2024)
11.4.5 Apotex Recent Development
11.5 Glemark Generics
11.5.1 Glemark Generics Company Detail
11.5.2 Glemark Generics Business Overview
11.5.3 Glemark Generics Amyotrophic Lateral Sclerosis Therapeutics Introduction
11.5.4 Glemark Generics Revenue in Amyotrophic Lateral Sclerosis Therapeutics Business (2019-2024)
11.5.5 Glemark Generics Recent Development
11.6 Covis Pharma
11.6.1 Covis Pharma Company Detail
11.6.2 Covis Pharma Business Overview
11.6.3 Covis Pharma Amyotrophic Lateral Sclerosis Therapeutics Introduction
11.6.4 Covis Pharma Revenue in Amyotrophic Lateral Sclerosis Therapeutics Business (2019-2024)
11.6.5 Covis Pharma Recent Development
11.7 Sun Pharma
11.7.1 Sun Pharma Company Detail
11.7.2 Sun Pharma Business Overview
11.7.3 Sun Pharma Amyotrophic Lateral Sclerosis Therapeutics Introduction
11.7.4 Sun Pharma Revenue in Amyotrophic Lateral Sclerosis Therapeutics Business (2019-2024)
11.7.5 Sun Pharma Recent Development
11.8 Lunan Pharma
11.8.1 Lunan Pharma Company Detail
11.8.2 Lunan Pharma Business Overview
11.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis Therapeutics Introduction
11.8.4 Lunan Pharma Revenue in Amyotrophic Lateral Sclerosis Therapeutics Business (2019-2024)
11.8.5 Lunan Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
